These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 2994377

  • 1. Effect of the radioprotector WR 2721 on the response of metastatic Lewis lung carcinoma colonies to alkylating agents.
    Wist EA.
    Acta Radiol Oncol; 1985; 24(3):259-62. PubMed ID: 2994377
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721.
    Wasserman TH, Phillips TL, Ross G, Kane LJ.
    Cancer Clin Trials; 1981; 4(1):3-6. PubMed ID: 6260393
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
    Adamson PC, Balis FM, Belasco JE, Lange B, Berg SL, Blaney SM, Craig C, Poplack DG.
    Cancer Res; 1995 Sep 15; 55(18):4069-72. PubMed ID: 7664282
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Modification by WR 2721 of the response to chemotherapy of tumours and normal tissues in the mouse.
    Twentyman PR.
    Br J Cancer; 1983 Jan 15; 47(1):57-63. PubMed ID: 6295428
    [Abstract] [Full Text] [Related]

  • 11. Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.
    Kligerman MM, Blumberg AL, Glick JH, Nelson DF, Glover D, Yuhas JM, Amols HI, Goodman RL.
    Cancer Clin Trials; 1981 Jan 15; 4(4):469-74. PubMed ID: 6274534
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Radiation protection of rat parenchymal hepatocytes with S-2-(3-aminopropylamino)ethylphosphorothioic acid.
    Jirtle RL, Pierce LJ, Crocker IR, Strom SC.
    Radiother Oncol; 1985 Nov 15; 4(3):231-7. PubMed ID: 3001838
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
    Teicher BA, Sotomayor EA, Huang ZD, Ara G, Holden S, Khandekar V, Chen YN.
    Cancer Chemother Pharmacol; 1993 Nov 15; 33(3):229-38. PubMed ID: 8269604
    [Abstract] [Full Text] [Related]

  • 18. Long-term effects of radioprotector WR-2721 on locomotor activity and body weight of mice following exposure to ionizing radiation.
    Landauer MR, Davis HD, Dominitz JA, Weiss JF.
    Toxicology; 1988 May 15; 49(2-3):315-23. PubMed ID: 2836973
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. WR-2721: enhanced chemoprotection by increasing cyclophosphamide activation with phenobarbitol.
    Glover DJ, Yuhas JM, Glick JH.
    Int J Radiat Oncol Biol Phys; 1982 May 15; 8(3-4):571-4. PubMed ID: 6286555
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.